Transjugular intrahepatic portosystemic shunts: Experience in the oncology setting

Cancer

Volumn 101, Issue 2, 2004, Pages 337-345

  Wallace, Michael J ^a   Madoff, David C ^a   Ahrar, Kamran ^a   Warneke, Carla L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Interventional procedure; Neoplasm; Portal hypertension; Portosystemic shunt

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; BILE DUCT CARCINOMA; BLEEDING; BUDD CHIARI SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; HYDROTHORAX; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; MALE; MEDICAL RECORD; OCCLUSION; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY; SHUNT THROMBOSIS; SOLID TUMOR; STOMACH DISEASE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; ASCITES; FEASIBILITY STUDIES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; HYDROTHORAX; HYPERTENSION, PORTAL; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; VARICOSE VEINS;

EID: 3042737581     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20367     Document Type: Article

References (43)

1. Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med. 1997;126:858-865.
2. Rossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet. 1997;349:1043-1049.
3. Pomier-Layrargues G, Villeneuve JP, Deschenes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut. 2001;48:390-396.
4. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342:1701-1707.
5. Gordon FD, Anastopoulos HT, Crenshaw W, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997;25:1366-1369.
6. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol. 2001;13: 529-534.
7. Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132-139.
8. Blum U, Rossle M, Haag K, et al. Budd-Chiari syndrome: technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Radiology. 1995;197:805-811.
9. Haskal ZJ, Martin L, Cardella JF, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. SCVIR Standards of Practice Committee. J Vasc Interv Radiol. 2001;12:131-136.
10. Michl P, Bilzer M, Waggershauser T, et al. Successful treatment of chronic Budd-Chiari syndrome with a transjugular intrahepatic portosystemic shunt. J Hepatol. 2000;32:516-520.
11. Strunk HM, Textor J, Brensing KA, Schild HH. Acute Budd-Chiari syndrome: treatment with transjugular intrahepatic portosystemic shunt. Cardiovasc Interv Radiol. 1997;20:311-313.
12. Shrestha R, Durham JD, Wachs M, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome. Am J Gastroenterol. 1997;92:2304-2306.
13. Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology. 1993;186:523-527.
14. Walser EM, NcNees SW, DeLa Pena O, et al. Portal venous thrombosis: percutaneous therapy and outcome. J Vasc Interv Radiol. 1998;9(1 Pt 1):119-127.
15. Yamagami T, Nakamura T, Tanaka O, Akada W, Takayama T, Maeda T. Transjugular intrahepatic portosystemic shunt after complete obstruction of portal vein. J Vasc Interv Radiol. 1999;10:575-578.
16. Matsui O, Yoshikawa J, Kadoya M, et al. Transjugular intrahepatic portosystemic shunt after previous recanalization of a chronically thrombosed portal vein via a transmesenteric approach. Cardiovasc Intervent Radiol. 1996;19:352-355.
17. Kawamata H, Kumazaki T, Kanazawa H, Takahashi S, Tajima H, Hayashi H. Transjugular intrahepatic portosystemic shunt in a patient with cavernomatous portal vein occlusion. Cardiovasc Intervent Radiol. 2000;23:145-149.
18. Wallace M, Swaim M. Transjugular intrahepatic portosystemic shunts through hepatic neoplasms. J Vasc Interv Radiol. 2003;14:501-507.
19. Bahramipour PF, Festa S, Biswal R, Wachsberg RH. Transjugular intrahepatic portosystemic shunt for the treatment of intractable ascites in a patient with polycystic liver disease. Cardiovasc Intervent Radiol. 2000;23:232-234.
20. Shin ES, Darcy MD. Transjugular intrahepatic portosystemic shunt placement in the setting of polycystic liver disease: questioning the contraindication. J Vasc Interv Radiol. 2001; 12:1099-1102.
21. Nakamura K, Hamuro M, Nishida N, Kaminou T, Satoh K, Matsuoka T. Hepatocellular carcinoma and portal hypertension: indication for transjugular intrahepatic portosystemic shunt [abstract]. Chicago: Radiological Society of North America, 2002;22:589.
22. Sakaguchi H, Uchida H, Maeda M, et al. Combined transjugular intrahepatic portosystemic shunt and segmental Lipiodol hepatic artery embolization for the treatment of esophagogastric varices and hepatocellular carcinoma in patients with cirrhosis: preliminary report. Cardiovasc Intervent Radiol. 1995;18:9-15.
23. Azoulay D, Buabse F, Damiano I, et al. Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. J Am Coll Surg. 2001;193:46-51.
24. Social Security Administration. U.S. Social Security Death Index web site. Available from URL: http://www.ancestry. com/ssdi/advanced.htm [accessed May, 2003].
25. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
26. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate - transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215-220.
27. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72(4 Pt 1):573-583.
28. Madoff DC, Perez-Young W, Wallace MJ, Skolkin MD, Toombs BD. Management of TIPS-related refractory hepatic encephalopathy with reduced Wallgraft endoprostheses. J Vasc Interv Radiol. 2003;14:369-374.
29. Zuckerman DA, Darcy MD, Bocchini TP, Hildebolt CF. Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. AJR Am J Roentgenol. 1997;169:1727-1731.
30. LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the Wallstent endoprosthesis: results in 100 patients. Radiology. 1993;187: 413-420.
31. Hidajat N, Vogl T, Stobbe H, et al. Transjugular intrahepatic portosystemic shunt. Experiences at a liver transplantation center. Acta Radiol. 2000;41:474-478.
32. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871.
33. Barton RE, Rosch J, Saxon RR, Lakin PC, Petersen BD, Keller FS. TIPS: short and long-term results: a survey of 1750 patients. Semin Interv Radiol. 1995;12:364.
34. Otal P, Smayra T, Bureau C, et al. Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. AJR Am J Roentgenol. 2002;178:141-147.
35. Jalan R, Lui HF, Redhead DN, Hayes PC. TIPSS 10 years on. Gut. 2000;46:578-581.
36. Forauer AR, McLean GK. Transjugular intrahepatic porto-systemic shunt constraining stent for the treatment of refractory postprocedural encephalopathy: a simple design utilizing a Palmaz stent and Wallstent. J Vasc Interv Radiol. 1998;9:443-446.
37. Saxon RS, Ross PL, Mendel-Hartvig J, et al. Transjugular intrahepatic portosystemic shunt patency and the importance of stenosis location in the development of recurrent symptoms. Radiology. 1998;207:683-693.
38. Saxon RR, Mendel-Hartvig J, Corless CL, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol. 1996;7:487-497.
39. Encarnacion CE, Palmaz JC, Rivera FJ, et al. Transjugular intrahepatic portosystemic shunt placement for variceal bleeding: predictors of mortality. J Vasc Interv Radiol. 1995; 6:687-694.
40. Coldwell DM, Ring EJ, Rees CR, et al. Multicenter investigation of the role of transjugular intrahepatic portosystemic shunt in management of portal hypertension. Radiology. 1995;196:335-340.
41. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123: 1839-1847.
42. Ferral H, Vasan R, Speeg KV, et al. Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol. 2002;13:1103-1108.
43. Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003; 52:879-885.